Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal
暂无分享,去创建一个
S. Larson | M. Fleisher | R. Tuttle | R. Robbins | A. Martorella | R. Grewal | M. Brokhin | Gal Omry | Andrew J. Martorella
[1] A. Pinchera,et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.
[2] B. Weintraub,et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. , 2006, The Journal of clinical endocrinology and metabolism.
[3] M. Luster,et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.
[4] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] R. Robbins,et al. Recombinant Human Thyrotropin and Thyroid Cancer Management , 2003 .
[6] H. Gerstein,et al. A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer , 2004 .
[7] P. Dasgupta,et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. , 2006, European urology.
[8] R. Robbins,et al. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. , 2003, The Journal of clinical endocrinology and metabolism.
[9] B. Weintraub,et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.
[10] R. Wahl,et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.
[11] M. Luster,et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. , 2005, Thyroid : official journal of the American Thyroid Association.
[12] M. Schlumberger. [Papillary and follicular thyroid carcinoma]. , 2000, Annales d'endocrinologie.
[13] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[14] S. Larson,et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.
[15] Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[16] Stephanie L. Lee,et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[17] G. Johnston,et al. Radioiodine therapy for thyroid cancer. , 1995, Endocrinology and metabolism clinics of North America.
[18] J. Luton,et al. [Thyroid tumors]. , 1998, Archives d'anatomie et de cytologie pathologiques.
[19] A. Pinchera,et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.
[20] B. Ferrell,et al. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. , 1997, Thyroid : official journal of the American Thyroid Association.
[21] L. Duntas,et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. , 2004, European journal of endocrinology.
[22] H. Gerstein,et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.
[23] S. Larson,et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.
[24] G. Mariani,et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.
[25] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.